The role of myeloid derived suppressor cells in musculoskeletal disorders

被引:5
|
作者
Ren, Yi [1 ]
Baecker, Henrik [2 ]
Mueller, Michael [1 ]
Kienzle, Arne [1 ,3 ]
机构
[1] Charite, Ctr Musculoskeletal Surg, Clin Orthoped, Berlin, Germany
[2] Auckland City Hosp, Dept Orthoped, Auckland, New Zealand
[3] Charite Univ Med Berlin, Berlin Inst Hlth, BIH Biomed Innovat Acad, BIH Charite Clinician Scientist Program, Berlin, Germany
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
myeloid derived suppressor cell (MDSC); bone metabolism; osteoclast; osteoblast; immune cells; inflammation; osteoimmunology; COLLAGEN-INDUCED ARTHRITIS; OSTEOCLAST DIFFERENTIATION; BONE-MARROW; TUMOR-IMMUNITY; CROSS-TALK; STEM-CELLS; PROMOTE; AGE; EXPRESSION; EXPANSION;
D O I
10.3389/fimmu.2023.1139683
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The immune system is closely linked to bone homeostasis and plays a pivotal role in several pathological and inflammatory conditions. Through various pathways it modulates various bone cells and subsequently sustains the physiological bone metabolism. Myeloid-derived suppressor cells (MDSCs) are a group of heterogeneous immature myeloid-derived cells that can exert an immunosuppressive function through a direct cell-to-cell contact, secretion of anti-inflammatory cytokines or specific exosomes. These cells mediate the innate immune response to chronic stress on the skeletal system. In chronic inflammation, MDSCs act as an inner offset to rebalance overactivation of the immune system. Moreover, they have been found to be involved in processes responsible for bone remodeling in different musculoskeletal disorders, autoimmune diseases, infection, and cancer. These cells can not only cause bone erosion by differentiating into osteoclasts, but also alleviate the immune reaction, subsequently leading to long-lastingly impacted bone remodeling. In this review, we discuss the impact of MDSCs on the bone metabolism under several pathological conditions, the involved modulatory pathways as well as potential therapeutic targets in MDSCs to improve bone health.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Myeloid derived-suppressor cells: their role in cancer and obesity
    Strand-Rosenberg, Suzanne
    CURRENT OPINION IN IMMUNOLOGY, 2018, 51 : 68 - 75
  • [22] Myeloid-derived suppressor cells and their role in pancreatic cancer
    Pergamo, M.
    Miller, G.
    CANCER GENE THERAPY, 2017, 24 (03) : 100 - 105
  • [23] Role of myeloid-derived suppressor cells in tumor immunotherapy
    Martin, Francois
    Apetoh, Lionel
    Ghiringhelli, Francois
    IMMUNOTHERAPY, 2012, 4 (01) : 43 - 57
  • [24] The role of myeloid-derived suppressor cells in glioma microenvironment
    Gao, Ce
    Wang, Aidong
    Shengwu Yixue Gongchengxue Zazhi/Journal of Biomedical Engineering, 2019, 36 (03): : 515 - 520
  • [25] Role of myeloid-derived suppressor cells in tumor recurrence
    Cole, Kathryn
    Al-Kadhimi, Zaid
    Talmadge, James E.
    CANCER AND METASTASIS REVIEWS, 2023, 42 (01) : 113 - 142
  • [26] Role of myeloid derived suppressor cells in tuberculosis infection and disease
    Nathella Pavan Kumar
    Rathinam Sridhar
    Vaithilingam V Banurekha
    Mohideen S Jawahar
    Thomas B Nutman
    Subash Babu
    BMC Infectious Diseases, 14 (Suppl 3)
  • [27] The role of myeloid-derived suppressor cells in tumor development
    Ortiz, Myrna L.
    Cheng, Pingyan
    Luetteke, Noreen
    Youn, Je-In
    Gabriloyich, Dmitry I.
    CANCER RESEARCH, 2011, 71
  • [28] The role of myeloid-derived suppressor cells in hematologic malignancies
    Gunes, Emine Gulsen
    Rosen, Steven T.
    Querfeld, Christiane
    CURRENT OPINION IN ONCOLOGY, 2020, 32 (05) : 518 - 526
  • [29] Role of myeloid derived suppressor cells in promoting ovarian cancer
    Rattan, Ramandeep
    Sakr, Sharif
    Quiles, Raymond
    Morris, Robert
    Buekers, Thomas
    Munkarah, Adnan
    Giri, Shailendra
    CANCER RESEARCH, 2018, 78 (13)
  • [30] The Role of Myeloid-Derived Suppressor Cells in Viral Infection
    O'Connor, Megan A.
    Rastad, Jessica L.
    Green, William R.
    VIRAL IMMUNOLOGY, 2017, 30 (02) : 82 - 97